Thank You!
Please check your email.

Senate Does Something Right For Once, Decides To Protect Medical Cannabis

  • Comments

The Senate did something right for once (two things if you count failing to repeal Obamacare). They decided to go against Jeff Sessions by renewing the Rohrabacher-Blumenauer (formerly Rohrabacher-Farr) amendment. Months ago, Sessions asked the Senate Appropriations Committee to give him the funds to allow his Justice Department to go after state medical cannabis providers and users, under the guise of enforcing federal law. The Rohrbacher-Blumenauer amendment disallows federal funds from going toward prosecuting people in compliance with their state’s medical cannabis laws.

The Senate Appropriations Committee decided to renew the amendment while voting on the Justice Department budget for the fiscal year 2018. Senator Patrick Leahy (D-VT) said before the vote, “It is more humane to regulate medical marijuana than to criminalize it. I don’t want them spending money pursuing medical marijuana patients who are following state law… We have more important things for the Justice Department to do than tracking down doctors or others, epileptics, who are using medical marijuana legally in their state.”

This does not look good for Sessions. The AG recently became the target of disparaging remarks by Trump in a recent interview, where he said that he would have never appointed the former Senator from Alabama, had he known he would recuse himself from the Russia investigation. Now, Sessions is being snubbed by his former colleagues, which some are speculating indicates that he is on his way out, either through termination or resignation.

This does not mean that the fight is over. It’s far from over. If the Democrats lose more seats in the Senate, then the Rohrabacher-Blumenauer amendment will be in danger again. For now though, patients using medical cannabis can rest a little easier tonight.

Source: Massroots

Image Source: cyverse.org


Got anything to add? Share with us in the comments below!

 

Categories:

Discussion

comments